Mektovi and Braftovi for lung cancer – pro
The combination of 2 drugs, Mektovi and Bartovi was recently approved for the RAF positive melanoma, as determined by an FDA approved test. It also has a breakthrough indication for colon cancer with cetuximab. However, there are no studies at all today could find full lung cancer that is the RAF positive. Therefore, there is no literature, guidelines, consensus statements, and this is an experimental/investigational treatment.
Dummer R, Ascierto PA, Gogas H, et al: Overall survival in COLUMBUS: A phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in BRAF-mutant melanoma. 2018 ASCO Annual Meeting. Abstract 9504. Presented June 4, 2018.
Sosman JA: Melanoma/skin cancers. 2018 Best of ASCO Chicago. Presented August 11, 2018.
Dummer R, Ascierto PA, Gogas HJ, et al: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19:P603-P615, 2018.